VIS, Inc. Opti-K® Q2 2026 Update

VIS, Inc. presents Opti-K®, a groundbreaking, patented eyecare technology designed to address prevalent vision impairments through a noninvasive, painless, and rapid procedure. Leveraging a unique thulium laser system, Opti-K® offers immediate improvements in low vision conditions including hyperopia, presbyopia, myopia, and age-related macular degeneration (AMD) while providing true multifocality. As an affordable, repeatable alternative to traditional eyewear or invasive surgeries like LASIK and PRK, Opti-K® minimizes risks, eliminates downtime, and requires no operating room—positioning it for widespread adoption in global markets. With recent regulatory milestones and imminent market entries, VIS, Inc. is poised for significant growth, inviting strategic investors to capitalize on this transformative opportunity in the multibillion-dollar eyecare sector.

Market Opportunity: Addressing a Massive Global Need

Vision impairments represent a vast and expanding market driven by aging populations and increasing prevalence of refractive errors:

- Presbyopia: Affects approximately 1.8 billion individuals worldwide, primarily those over 40, due to age-related lens stiffening, impairing near vision.
- Hyperopia (Farsightedness): Impacts about 1.94 billion people, where light focuses behind the retina, blurring close objects, and possibly distant objects.
- Myopia (Nearsightedness): Afflicts 2.6 billion adults and an estimated 720 million children aged 2-18 globally, with projections rising to 740 million children by 2050.
- Age-Related Macular Degeneration (AMD): The leading cause of vision loss in adults over 50, affecting ~220 million people in 2025 and expected to reach ~288 million by 2040.

These conditions create ongoing demand for solutions, with current options—eyeglasses, contact lenses, or surgical interventions—often limited by cost, inconvenience, or risks such as sight-threatening complications. Opti-K® targets this underserved market, offering a scalable, patient-centric approach with potential for substantial revenue streams.

Innovative Solution: Opti-K® Technology

Opti-K®, or Optimal Keratoplasty, utilizes an infrared thulium laser-based optical delivery system—the only such technology in the FDA's presbyopia pipeline.

Key features include:

- **Rapid and Efficient Procedure:** Completed in under 3 seconds per eye (total setup to completion under 5 minutes for both eyes), delivering immediate results with no recovery time or post-operative medications.

- **Affordability and Accessibility:** Patient costs comparable to or lower than eyewear; for providers, a rental model reduces upfront expenses, requiring only a standard exam room setup—no surgical suite needed.
- **Safety and Repeatability:** Non-invasive, pain-free, and without cutting or epithelial disruption. Results last 6 months to 1 year for emmetropes, up to 2 years for presbyopes, and up to 4 years for AMD patients, with safe repeatability to accommodate progressive conditions.
- **Compact and Mobile Design:** A cart-based device (22" x 8.5" x 16.25") with an iPad interface for precise centration, enabling multi-office use and seamless integration into clinical practices.

Competitive Advantages

Opti-K® outperforms existing alternatives by avoiding the invasiveness and risks of procedures like LASIK, PRK, or intraocular lenses (IOLs). Its noninvasive nature, immediate outcomes, and low operational requirements lower barriers to entry for ophthalmologists and optometrists, fostering broad adoption. The mobile, user-friendly platform supports a comanaged care model, enhancing referral networks and market penetration.

Investment Invitation

Opti-K® is set to disrupt the eyecare industry, tapping into a global market exceeding billions in annual value. With proven technology, regulatory momentum, and a clear path to international expansion, VIS, Inc. offers a compelling opportunity for investors seeking high-impact returns in healthcare innovation. Contact us directly to explore partnership possibilities and join in revolutionizing vision care.



Key Milestones and Progress

VIS, Inc. has achieved critical regulatory and operational advancements, demonstrating strong execution:

- April 2023: FDA approval for Investigational Device Exemption (IDE) as a Class III device.
- August 2023: Launch of FDA PMA Phase III clinical trial.
- December 2023: Health Canada approval for Investigational Testing Authorization (ITA) for AMD treatment.
- August 2024: Health Canada ITA approval for presbyopia treatment.
- October 2024: ISO 13485:2016 and Medical Device Single Audit Program (MDSAP) certifications.
- September 2025: Complete Billing of Materials (BOM) and CAD system designs for Opti-K.
- March 2025: Medical Device License (MDL) from Health Canada, enabling market entry.
- December 2025: Filing of non-provisional patent for myopia treatment with USPTO.
- January 2026: Canadian market launch for hyperopia, presbyopia, and AMD as fee-for-service procedures; establishment of Canadian Advisory Board and Optometrist Comanaged Care Plan.
- February 2026: Initiation of UKCA and CE marking applications, targeting UK and EU entry by Q3 2026.
- Launched Canadian Market Entry as fee-for-service In partnership with the Clarity Eyre Institute, serving the entire Greater Toronto Area (GTA) with 7 offices, 10 surgical centers, and 50 doctors.

These achievements underscore VIS, Inc.'s trajectory toward commercialization and revenue generation, with Canadian operations already underway.

Investment Invitation

Opti-K® is set to disrupt the eyecare industry, tapping into a global market exceeding billions in annual value. With proven technology, regulatory momentum, and a clear path to international expansion, VIS, Inc. offers a compelling opportunity for investors seeking high-impact returns in healthcare innovation. Contact us directly to explore partnership possibilities and join in revolutionizing vision care

For more information, please contact VIS CCO Don Schwall directly:

Donald B. Schwall, Jr.
Chief Commercial Officer

ir@viscorrect.com | +1 561 819 8300
www.viscorrect.com | www.opti-k.com